Trial Profile
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Condylomata acuminata; Gynaecological cancer; Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics
- 10 Feb 2021 Status changed from active, no longer recruiting to completed.
- 05 Dec 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 11 Dec 2015 New trial record